Stonepine Capital Management LLC Has $1.77 Million Stake in Aytu BioPharma Inc. $AYTU

Stonepine Capital Management LLC increased its position in Aytu BioPharma Inc. (NASDAQ:AYTU) by 75.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 812,676 shares of the company’s stock after purchasing an additional 348,955 shares during the quarter. Aytu BioPharma makes up 1.7% of Stonepine Capital Management LLC’s portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned approximately 0.09% of Aytu BioPharma worth $1,772,000 at the end of the most recent quarter.

Separately, FNY Investment Advisers LLC acquired a new position in shares of Aytu BioPharma in the 2nd quarter valued at $78,000. Institutional investors and hedge funds own 33.49% of the company’s stock.

Aytu BioPharma Stock Performance

NASDAQ AYTU opened at $2.13 on Thursday. Aytu BioPharma Inc. has a 1-year low of $0.95 and a 1-year high of $2.82. The company has a 50 day moving average of $2.14 and a 200-day moving average of $2.19. The company has a current ratio of 1.23, a quick ratio of 1.08 and a debt-to-equity ratio of 0.45. The firm has a market cap of $21.70 million, a price-to-earnings ratio of -0.70 and a beta of 0.28.

Aytu BioPharma (NASDAQ:AYTU) last announced its earnings results on Thursday, November 13th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Aytu BioPharma had a positive return on equity of 17.86% and a negative net margin of 20.52%.The business had revenue of $13.89 million during the quarter, compared to analyst estimates of $17.92 million.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on AYTU. Wall Street Zen lowered shares of Aytu BioPharma from a “buy” rating to a “hold” rating in a research report on Friday, September 26th. Ascendiant Capital Markets lifted their price objective on Aytu BioPharma from $12.00 to $12.50 and gave the company a “buy” rating in a report on Thursday, September 25th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aytu BioPharma in a research note on Tuesday, October 14th. Zacks Research raised Aytu BioPharma from a “strong sell” rating to a “hold” rating in a report on Monday, November 24th. Finally, Maxim Group cut their target price on Aytu BioPharma from $9.00 to $7.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $9.17.

Aytu BioPharma Profile

Aytu Biopharma, Inc is a specialty pharmaceutical company, which engages in identifying, acquiring, and commercializing novel products. It operates through the Rx and Consumer Health segments. The RX segment consists of various prescription pharmaceutical products sold through third parties. The Consumer Health segment includes various consumer health products sold directly to consumers.